Cargando…
RNA Interference Technologies and Therapeutics: From Basic Research to Products
RNA interference (RNAi) is a natural cellular process that regulates gene expression by a highly precise mechanism of sequence-directed gene silencing at the stage of translation by degrading specific messenger RNAs or blocking translation. In recent years, the use of RNAi for therapeutic applicatio...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099360/ https://www.ncbi.nlm.nih.gov/pubmed/19754220 http://dx.doi.org/10.2165/11318190-000000000-00000 |
_version_ | 1783511315000590336 |
---|---|
author | López-Fraga, Marta Martínez, Tamara Jiménez, Ana |
author_facet | López-Fraga, Marta Martínez, Tamara Jiménez, Ana |
author_sort | López-Fraga, Marta |
collection | PubMed |
description | RNA interference (RNAi) is a natural cellular process that regulates gene expression by a highly precise mechanism of sequence-directed gene silencing at the stage of translation by degrading specific messenger RNAs or blocking translation. In recent years, the use of RNAi for therapeutic applications has gained considerable momentum. It has been suggested that most of the novel disease-associated targets that have been identified are not ‘druggable’ with conventional approaches. However, any disease-causing gene and any cell type or tissue can potentially be targeted with RNAi. This review focuses on the current knowledge of RNAi mechanisms and the safety issues associated with its potential use in a therapeutic setting. Some of the most important aspects to consider when working towards the application of RNAi-based products in a clinical setting have been related to achieving high efficacies and enhanced stability profiles through a careful design of the nucleic acid sequence and the introduction of chemical modifications, but most of all, to developing improved delivery systems, both viral and non-viral. These new delivery systems allow for these products to reach the desired target cells, tissues or organs in a highly specific manner and after administration of the lowest possible doses. Various routes of application and target locations are currently being addressed in order to develop effective delivery systems for different targets and pathologies, including infectious pathologies, genetic pathologies and diseases associated with dysregulation of endogenous microRNAs. As with any new technology, several challenges and important aspects to be considered have risen on the road to clinical intervention, e.g. correct design of preclinical toxicology studies, regulatory concerns, and intellectual property protection. The main advantages related to the use of RNAi-based products in a clinical setting, and the latest clinical and preclinical studies using these compounds, are reviewed. |
format | Online Article Text |
id | pubmed-7099360 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-70993602020-03-27 RNA Interference Technologies and Therapeutics: From Basic Research to Products López-Fraga, Marta Martínez, Tamara Jiménez, Ana BioDrugs Review Article RNA interference (RNAi) is a natural cellular process that regulates gene expression by a highly precise mechanism of sequence-directed gene silencing at the stage of translation by degrading specific messenger RNAs or blocking translation. In recent years, the use of RNAi for therapeutic applications has gained considerable momentum. It has been suggested that most of the novel disease-associated targets that have been identified are not ‘druggable’ with conventional approaches. However, any disease-causing gene and any cell type or tissue can potentially be targeted with RNAi. This review focuses on the current knowledge of RNAi mechanisms and the safety issues associated with its potential use in a therapeutic setting. Some of the most important aspects to consider when working towards the application of RNAi-based products in a clinical setting have been related to achieving high efficacies and enhanced stability profiles through a careful design of the nucleic acid sequence and the introduction of chemical modifications, but most of all, to developing improved delivery systems, both viral and non-viral. These new delivery systems allow for these products to reach the desired target cells, tissues or organs in a highly specific manner and after administration of the lowest possible doses. Various routes of application and target locations are currently being addressed in order to develop effective delivery systems for different targets and pathologies, including infectious pathologies, genetic pathologies and diseases associated with dysregulation of endogenous microRNAs. As with any new technology, several challenges and important aspects to be considered have risen on the road to clinical intervention, e.g. correct design of preclinical toxicology studies, regulatory concerns, and intellectual property protection. The main advantages related to the use of RNAi-based products in a clinical setting, and the latest clinical and preclinical studies using these compounds, are reviewed. Springer International Publishing 2012-08-16 2009 /pmc/articles/PMC7099360/ /pubmed/19754220 http://dx.doi.org/10.2165/11318190-000000000-00000 Text en © Adis Data Information BV 2009 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Article López-Fraga, Marta Martínez, Tamara Jiménez, Ana RNA Interference Technologies and Therapeutics: From Basic Research to Products |
title | RNA Interference Technologies and Therapeutics: From Basic Research to Products |
title_full | RNA Interference Technologies and Therapeutics: From Basic Research to Products |
title_fullStr | RNA Interference Technologies and Therapeutics: From Basic Research to Products |
title_full_unstemmed | RNA Interference Technologies and Therapeutics: From Basic Research to Products |
title_short | RNA Interference Technologies and Therapeutics: From Basic Research to Products |
title_sort | rna interference technologies and therapeutics: from basic research to products |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099360/ https://www.ncbi.nlm.nih.gov/pubmed/19754220 http://dx.doi.org/10.2165/11318190-000000000-00000 |
work_keys_str_mv | AT lopezfragamarta rnainterferencetechnologiesandtherapeuticsfrombasicresearchtoproducts AT martineztamara rnainterferencetechnologiesandtherapeuticsfrombasicresearchtoproducts AT jimenezana rnainterferencetechnologiesandtherapeuticsfrombasicresearchtoproducts |